fingolimod hydrochloride has been researched along with Cardiotoxicity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arriazu, E; Cayuela, ML; García-Ramírez, P; Guruceaga, E; Marcotegui, N; Martínez-Balsalobre, E; Mateos, MC; Odero, MD; Oyarzábal, J; Peris, I; Pippa, R; Prósper, F; Rabal, O; Vicente, C | 1 |
| Koch-Henriksen, N; Magyari, M; Oturai, AB; Sellebjerg, F; Sørensen, PS; Voldsgaard, A | 1 |
2 other study(ies) available for fingolimod hydrochloride and Cardiotoxicity
| Article | Year |
|---|---|
A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Cardiotoxicity; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Female; Fingolimod Hydrochloride; Heart Rate; Histone Chaperones; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Binding; Protein Phosphatase 2; Toxicity Tests, Acute; Xenograft Model Antitumor Assays; Zebrafish | 2020 |
Early safety and efficacy of fingolimod treatment in Denmark.
Topics: Adult; Aged; Cardiotoxicity; Denmark; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Respiration | 2017 |